PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028054
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028054
Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of cancer vaccines Market
The global cancer vaccines market was valued at USD 13.86 billion in 2025 and is projected to grow to USD 15.93 billion in 2026, reaching USD 62.93 billion by 2034, registering a strong CAGR of 18.74% during the forecast period (2026-2034). North America dominated the market with a 35.97% share in 2025, supported by advanced healthcare infrastructure and high cancer prevalence.
Cancer continues to be a major global health burden, with rising incidence rates driving demand for preventive and therapeutic vaccines. Increasing awareness, improved diagnostics, and expanding immunization programs are further strengthening market growth.
Market Trends
A key trend shaping the market is the rising investment in research and development (R&D) for preventive and therapeutic cancer vaccines. Pharmaceutical and biotech companies are focusing on developing innovative vaccines using advanced technologies such as mRNA platforms, AI-based modeling, and genomic sequencing.
Additionally, collaborations between research institutes and companies are accelerating innovation. Increasing clinical trials for vaccines targeting conditions such as Lynch Syndrome and melanoma are further boosting market expansion.
Market Growth Factors
Increasing Cancer Incidence
The growing global burden of cancer is a major driver for market growth. Rising cases of cervical, lung, breast, and prostate cancers are increasing demand for preventive vaccines. Factors such as smoking, pollution, unhealthy lifestyle, and infections like HPV contribute significantly to cancer prevalence.
Government Initiatives and Immunization Programs
Governments and global organizations are promoting vaccination programs to reduce cancer incidence. Public health campaigns and HPV vaccination initiatives are improving awareness and adoption, especially in developing countries.
Technological Advancements
Innovations in personalized vaccines, neoantigen targeting, and immunotherapy are enhancing treatment outcomes. Integration of AI and biotechnology is enabling faster development of highly targeted cancer vaccines.
Restraining Factors
Despite strong growth, the market faces certain limitations. One major challenge is the rise of personalized medicine, which offers targeted therapies with better outcomes. These treatments reduce reliance on traditional vaccines.
Additionally, limited approvals for certain cancer types and high development costs also restrict widespread adoption of cancer vaccines.
Segmentation Analysis
By Type
The preventive segment dominated the market, accounting for 91.52% share in 2026, driven by increased HPV vaccine adoption and growing focus on cancer prevention. The therapeutic segment is expected to grow at a faster rate due to ongoing research and product development.
By Technology
The molecular-based segment held the largest share (92.27% in 2026) due to advancements in recombinant and mRNA vaccines. Vector-based and cell-based technologies are also gaining traction.
By Indication
The cervical cancer segment dominated the market (88.89% in 2026) due to rising HPV infections and increasing awareness. Other segments such as lung, prostate, and bladder cancer are expected to grow steadily.
By Distribution Channel
The hospital segment led the market with a 55.39% share in 2026, supported by high patient visits and better vaccine accessibility. Government supply channels are also expanding due to mass immunization initiatives.
Regional Insights
North America
North America accounted for USD 4.99 billion in 2025 and is expected to reach USD 5.71 billion in 2026. Growth is driven by high cancer incidence, strong R&D ecosystem, and presence of leading companies.
Europe
Europe held USD 4.08 billion in 2025, supported by rising investments in clinical trials and vaccine development. Countries such as Germany, the UK, and France are key contributors.
Asia Pacific
Asia Pacific reached USD 4.12 billion in 2025 and is projected to grow significantly due to increasing awareness, government initiatives, and expanding healthcare infrastructure. Countries like China, India, and Japan are leading growth.
Latin America & Middle East & Africa
These regions showed moderate growth, with USD 0.39 billion and USD 0.28 billion respectively in 2025, driven by rising cancer prevalence and improving access to healthcare services.
Competitive Landscape
The market is highly competitive with key players such as Merck & Co., Inc., GlaxoSmithKline plc, Dendreon Pharmaceuticals LLC., and Serum Institute of India Pvt. Ltd. leading innovation.
Companies are focusing on strategic collaborations, acquisitions, and clinical trials to strengthen their market position. Increasing investments in manufacturing and distribution are also supporting global expansion.
Conclusion
The cancer vaccines market is poised for significant growth, driven by rising cancer incidence, technological advancements, and increasing global focus on preventive healthcare. With strong R&D pipelines, expanding immunization programs, and innovations such as mRNA and personalized vaccines, the market is expected to transform cancer treatment and prevention. Despite challenges such as high costs and competition from personalized therapies, continuous innovation and government support will ensure sustained market expansion through 2034.
Segmentation
By Type
- Preventive
- Therapeutic
By Technology
- Molecular-based
- Vector-based
- Cell-based
By Indication
- Cervical Cancer
- Bladder Cancer
- Prostate Cancer
- Lung Cancer
- Others
By Distribution Channel
- Hospitals
- Government & Organization Supply
- Others
By Region
- North America (By Type, By Technology, By Indication, By Distribution Channel, By Country)
- U.S.
- Canada
- Europe (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
- France
- Italy
- Spain
- U.K.
- Germany
- Rest of Europe
- Asia Pacific (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Different Cancers, by Key Countries, 2025
- 4.2. Overview of Regulatory Scenario by Key Countries/Regions
- 4.3. Pipeline Analysis, Key Players
- 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships
- 4.5. New Product Launches
- 4.6. Impact of COVID-19 on Global Cancer Vaccines Market
5. Global Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Preventive
- 5.1.2. Therapeutic
- 5.2. Market Analysis, Insights and Forecast - By Technology
- 5.2.1. Molecular-based
- 5.2.2. Vector-based
- 5.2.3. Cell-based
- 5.3. Market Analysis, Insights and Forecast - By Indication
- 5.3.1. Cervical Cancer
- 5.3.2. Bladder Cancer
- 5.3.3. Prostate Cancer
- 5.3.4. Lung Cancer
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospitals
- 5.4.2. Government & Organization Supply
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Preventive
- 6.1.2. Therapeutic
- 6.2. Market Analysis, Insights and Forecast - By Technology
- 6.2.1. Molecular-based
- 6.2.2. Vector-based
- 6.2.3. Cell-based
- 6.3. Market Analysis, Insights and Forecast - By Indication
- 6.3.1. Cervical Cancer
- 6.3.2. Bladder Cancer
- 6.3.3. Prostate Cancer
- 6.3.4. Lung Cancer
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospitals
- 6.4.2. Government & Organization Supply
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Preventive
- 7.1.2. Therapeutic
- 7.2. Market Analysis, Insights and Forecast - By Technology
- 7.2.1. Molecular-based
- 7.2.2. Vector-based
- 7.2.3. Cell-based
- 7.3. Market Analysis, Insights and Forecast - By Indication
- 7.3.1. Cervical Cancer
- 7.3.2. Bladder Cancer
- 7.3.3. Prostate Cancer
- 7.3.4. Lung Cancer
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospitals
- 7.4.2. Government & Organization Supply
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. France
- 7.5.2. Italy
- 7.5.3. Spain
- 7.5.4. U.K.
- 7.5.5. Germany
- 7.5.6. Rest of Europe
8. Asia Pacific Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Preventive
- 8.1.2. Therapeutic
- 8.2. Market Analysis, Insights and Forecast - By Technology
- 8.2.1. Molecular-based
- 8.2.2. Vector-based
- 8.2.3. Cell-based
- 8.3. Market Analysis, Insights and Forecast - By Indication
- 8.3.1. Cervical Cancer
- 8.3.2. Bladder Cancer
- 8.3.3. Prostate Cancer
- 8.3.4. Lung Cancer
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospitals
- 8.4.2. Government & Organization Supply
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Preventive
- 9.1.2. Therapeutic
- 9.2. Market Analysis, Insights and Forecast - By Technology
- 9.2.1. Molecular-based
- 9.2.2. Vector-based
- 9.2.3. Cell-based
- 9.3. Market Analysis, Insights and Forecast - By Indication
- 9.3.1. Cervical Cancer
- 9.3.2. Bladder Cancer
- 9.3.3. Prostate Cancer
- 9.3.4. Lung Cancer
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospitals
- 9.4.2. Government & Organization Supply
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Preventive
- 10.1.2. Therapeutic
- 10.2. Market Analysis, Insights and Forecast - By Technology
- 10.2.1. Molecular-based
- 10.2.2. Vector-based
- 10.2.3. Cell-based
- 10.3. Market Analysis, Insights and Forecast - By Indication
- 10.3.1. Cervical Cancer
- 10.3.2. Bladder Cancer
- 10.3.3. Prostate Cancer
- 10.3.4. Lung Cancer
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospitals
- 10.4.2. Government & Organization Supply
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Dendreon Pharmaceuticals LLC.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Serum Institute of India Pvt. Ltd.
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. GlaxoSmithKline plc
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Walvax Biotechnology Co., Ltd.
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Synthaverse S.A.
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Center of Molecular Immunology
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Ferring B.V.
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Wantai BioPharm
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Dynavax Technologies Corporation
- 11.2.10.1. Overview
- 11.2.10.2. Products & Services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.1. Dendreon Pharmaceuticals LLC.
List of Tables
- Table 1: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 3: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 4: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 5: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 7: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 8: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 9: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 10: North America Cancer Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 12: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 13: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 14: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 15: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 17: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 18: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 19: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 22: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 23: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 24: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 25: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 27: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 28: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 29: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 30: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Cancer Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Cancer Vaccines Market Value Share (%), by Type, 2025 & 2034
- Figure 3: Global Cancer Vaccines Market Value Share (%), by Technology, 2025 & 2034
- Figure 4: Global Cancer Vaccines Market Value Share (%), by Indication, 2025 & 2034
- Figure 5: Global Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Cancer Vaccines Market Value (USD billion), by Region, 2025 & 2034
- Figure 7: North America Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 8: North America Cancer Vaccines Market Value Share (%), by Type, 2025
- Figure 9: North America Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 10: North America Cancer Vaccines Market Value Share (%), by Technology, 2025
- Figure 11: North America Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 12: North America Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 13: North America Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: North America Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 15: North America Cancer Vaccines Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Cancer Vaccines Market Value Share (%), By Country, 2025
- Figure 17: Europe Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 18: Europe Cancer Vaccines Market Value Share (%), by Type, 2025
- Figure 19: Europe Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 20: Europe Cancer Vaccines Market Value Share (%), by Technology, 2025
- Figure 21: Europe Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 22: Europe Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 23: Europe Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 24: Europe Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 25: Europe Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 28: Asia Pacific Cancer Vaccines Market Value Share (%), by Type, 2025
- Figure 29: Asia Pacific Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 30: Asia Pacific Cancer Vaccines Market Value Share (%), by Technology, 2025
- Figure 31: Asia Pacific Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 32: Asia Pacific Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 33: Asia Pacific Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Asia Pacific Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 38: Latin America Cancer Vaccines Market Value Share (%), by Type, 2025
- Figure 39: Latin America Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 40: Latin America Cancer Vaccines Market Value Share (%), by Technology, 2025
- Figure 41: Latin America Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 42: Latin America Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 43: Latin America Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 44: Latin America Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 45: Latin America Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 48: Middle East & Africa Cancer Vaccines Market Value Share (%), by Type, 2025
- Figure 49: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 50: Middle East & Africa Cancer Vaccines Market Value Share (%), by Technology, 2025
- Figure 51: Middle East & Africa Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 52: Middle East & Africa Cancer Vaccines Market Value Share (%), by Indication, 2025
- Figure 53: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 55: Middle East & Africa Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 57: Global Cancer Vaccines Market Share (%), By Company, 2025
